Ovid Therapeutics (NASDAQ:OVID) Price Target Lowered to $1.50 at HC Wainwright
Ovid Therapeutics (NASDAQ:OVID – Free Report) had its price objective reduced by HC Wainwright from $2.00 to $1.50 in a research report report published on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Several other brokerages have also weighed in on OVID. Wedbush reissued an “outperform” rating and issued a $3.00 […]
Ovid Therapeutics (NASDAQ:OVID – Free Report) had its price objective reduced by HC Wainwright from $2.00 to $1.50 in a research report report published on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Several other brokerages have also weighed in on OVID. Wedbush reissued an “outperform” rating and issued a $3.00 […]
